Indacaterol, a once‐daily beta2‐agonist, versus twice‐daily beta2‐agonists or placebo for chronic obstructive pulmonary disease

Overview of attention for article published in Cochrane database of systematic reviews, January 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
Good Attention Score compared to outputs of the same age and source (79th percentile)

So far, Altmetric has seen 6 public wall posts from 4 users.

Newly published #CochraneEvidence: For patients with stable COPD, use of indacaterol versus placebo results in statistically…

Nova #evidenciaCochrane. Para pacientes com #DPOC (doença pulmonar obstrutiva crônica) estável: a utilização de indacaterol…

Newly published #CochraneEvidence: For patients with stable COPD, use of indacaterol versus placebo results in statistically…

New #Cochrane Review: Indacaterol, a once-daily beta2-agonist, versus twice-daily beta2-agonists or placebo for COPD http://ow.ly…

Quality of evidence was high to moderate - see SOF tables: http://ow.ly/H9OFM onlinelibrary.wiley.com

RT @tlassers: New review shows once daily bronchodilator has similar effects to twice daily preparation in #COPD http://ow.ly/H9N…